Literature DB >> 21068733

Paying "particle" attention to novel melanoma treatment strategies.

Michele B Weiss1, Andrew E Aplin.   

Abstract

Malignant melanoma remains the deadliest form of skin cancer because of its highly aggressive nature and the lack of effective treatments. Recent investigations into alternative treatment strategies have highlighted the exciting potential of nanoparticles to increase melanoma cell delivery and the efficacy of small interfering RNAs (siRNAs) and pharmacological inhibitors. In this issue, Chen et al. report a new liposomal nanoparticle for c-Myc siRNA delivery, noting it to be highly effective in reducing c-Myc expression and inhibiting melanoma tumor growth in mouse models. This preclinical study underscores the importance of investigating nanoparticle treatment options for chemoresistant melanomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21068733      PMCID: PMC9020221          DOI: 10.1038/jid.2010.293

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   7.590


  9 in total

1.  Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma.

Authors:  D A Ross; G D Wilson
Journal:  Br J Surg       Date:  1998-01       Impact factor: 6.939

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells.

Authors:  Sudha Mannava; Vladimir Grachtchouk; Linda J Wheeler; Michael Im; Dazhong Zhuang; Elena G Slavina; Christopher K Mathews; Donna S Shewach; Mikhail A Nikiforov
Journal:  Cell Cycle       Date:  2008-06-03       Impact factor: 4.534

4.  C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.

Authors:  D Zhuang; S Mannava; V Grachtchouk; W-H Tang; S Patil; J A Wawrzyniak; A E Berman; T J Giordano; E V Prochownik; M S Soengas; M A Nikiforov
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

5.  Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy.

Authors:  Sudipta Basu; Rania Harfouche; Shivani Soni; Geetanjali Chimote; Raghunath A Mashelkar; Shiladitya Sengupta
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-21       Impact factor: 11.205

6.  Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

Authors:  Melissa A Tran; Raghavendra Gowda; Arati Sharma; Eun-Joo Park; James Adair; Mark Kester; Nadine Barrie Smith; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

7.  Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.

Authors:  Gabriel J Villares; Maya Zigler; Hua Wang; Vladislava O Melnikova; Hong Wu; Ran Friedman; Michael C Leslie; Pablo E Vivas-Mejia; Gabriel Lopez-Berestein; Anil K Sood; Menashe Bar-Eli
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

8.  WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth.

Authors:  D E Zamora-Avila; P Zapata-Benavides; M A Franco-Molina; S Saavedra-Alonso; L M Trejo-Avila; D Reséndez-Pérez; J L Méndez-Vázquez; J Isaias-Badillo; C Rodríguez-Padilla
Journal:  Cancer Gene Ther       Date:  2009-05-22       Impact factor: 5.987

9.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330

  9 in total
  3 in total

Review 1.  Applications of nanotechnology in dermatology.

Authors:  Lisa A DeLouise
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

2.  Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials.

Authors:  P Severino; J F Fangueiro; S V Ferreira; R Basso; M V Chaud; M H A Santana; A Rosmaninho; E B Souto
Journal:  Clin Transl Oncol       Date:  2013-01-24       Impact factor: 3.405

Review 3.  Drug delivery nanoparticles in skin cancers.

Authors:  Chiara Dianzani; Gian Paolo Zara; Giovanni Maina; Piergiorgio Pettazzoni; Stefania Pizzimenti; Federica Rossi; Casimiro Luca Gigliotti; Eric Stefano Ciamporcero; Martina Daga; Giuseppina Barrera
Journal:  Biomed Res Int       Date:  2014-07-02       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.